X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business Unit (GEM BU).
Lead Product(s): Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area: Neurology Product Name: Neosaldina
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hypera Pharma
Deal Size: $825.0 million Upfront Cash: Undisclosed
Deal Type: Divestment January 29, 2021
Details:
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.
Lead Product(s): Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hypera Pharma
Deal Size: $825.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
